| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.2147/CIA.S74042 |
| P8608 | Fatcat ID | release_zujf3cmytrh2lf5kk75hj4sbji |
| P3181 | OpenCitations bibliographic resource ID | 782728 |
| P932 | PMC publication ID | 4360697 |
| P698 | PubMed publication ID | 25792818 |
| P2093 | author name string | Xiaohua Li | |
| Sean Leng | |||
| Dalin Song | |||
| P2860 | cites work | The metabolic syndrome, inflammation, and risk of cognitive decline | Q45145786 |
| Diabetes mellitus in midlife and the risk of dementia three decades later | Q45158820 | ||
| Midlife cardiovascular risk factors and risk of dementia in late life | Q45236740 | ||
| Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. | Q46017108 | ||
| Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin | Q46428482 | ||
| Activation of glycogen synthase kinase-3 induces Alzheimer-like tau hyperphosphorylation in rat hippocampus slices in culture | Q46549772 | ||
| Alzheimer's Disease | Q22248111 | ||
| Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin | Q22250892 | ||
| Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial | Q24607545 | ||
| Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study | Q24628969 | ||
| Type 2 diabetes and cognitive impairment: linking mechanisms | Q26822993 | ||
| Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 | Q27860575 | ||
| The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics | Q27860914 | ||
| Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | Q27860959 | ||
| Glucagon-like peptide-1 receptor is involved in learning and neuroprotection | Q28202403 | ||
| GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides | Q28205921 | ||
| The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes | Q28273497 | ||
| Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling | Q28574687 | ||
| Mechanisms underlying insulin deficiency-induced acceleration of β-amyloidosis in a mouse model of Alzheimer's disease | Q28731520 | ||
| Alzheimer's disease: the amyloid cascade hypothesis | Q29547160 | ||
| The metabolic syndrome--a new worldwide definition | Q29615125 | ||
| Metformin and reduced risk of cancer in diabetic patients | Q29616275 | ||
| Amyloid deposition as the central event in the aetiology of Alzheimer's disease | Q29619450 | ||
| Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement | Q29619465 | ||
| Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? | Q29619535 | ||
| A central role for JNK in obesity and insulin resistance | Q29619778 | ||
| Diabetes mellitus and risk of dementia: A meta-analysis of prospective observational studies | Q33607787 | ||
| Fasting plasma insulin, C-peptide and cognitive change in older men without diabetes: results from the Physicians' Health Study II. | Q33906585 | ||
| Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial | Q33988701 | ||
| Aggregation of vascular risk factors and risk of incident Alzheimer disease | Q33989502 | ||
| Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review | Q34100675 | ||
| An 18-year follow-up of overweight and risk of Alzheimer disease | Q34214251 | ||
| Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance | Q34225645 | ||
| Anorexia, sarcopenia, and aging | Q34305739 | ||
| Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin | Q34335548 | ||
| Thiazolidinediones | Q34346862 | ||
| Therapy for Alzheimer's Disease: How Effective are Current Treatments? | Q34409349 | ||
| Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study | Q34467303 | ||
| Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine | Q34474707 | ||
| Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease | Q34489699 | ||
| The influence of glucose-lowering therapies on cancer risk in type 2 diabetes | Q34609508 | ||
| Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study | Q34655640 | ||
| Does insulin dysfunction play a role in Alzheimer's disease? | Q34708071 | ||
| Identification and characterization of metabolically benign obesity in humans | Q34807153 | ||
| Type 2 diabetes and late-onset Alzheimer's disease | Q35123597 | ||
| Causative and susceptibility genes for Alzheimer's disease: a review. | Q35146030 | ||
| GSK3 and Alzheimer's Disease: Facts and Fiction…. | Q35182282 | ||
| Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial | Q35679839 | ||
| The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease | Q35749645 | ||
| Physiology of incretins in health and disease | Q35760279 | ||
| An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers | Q35858008 | ||
| Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline | Q35858095 | ||
| The role of inflammation in Alzheimer's disease | Q35913633 | ||
| Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease | Q35997824 | ||
| The role of insulin receptor signaling in the brain | Q36056044 | ||
| Inflammation and the etiology of type 2 diabetes | Q36180883 | ||
| New twist on neuronal insulin receptor signaling in health, disease, and therapeutics | Q36279575 | ||
| Cognitive decline and dementia in diabetes--systematic overview of prospective observational studies | Q36311526 | ||
| Risk of dementia in diabetes mellitus: a systematic review | Q36345254 | ||
| Brain and brawn: parallels in oxidative strength | Q36375908 | ||
| Midlife and late-life obesity and the risk of dementia: cardiovascular health study | Q36441882 | ||
| Metabolic syndrome and dementia risk in a multiethnic elderly cohort | Q36498733 | ||
| Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype | Q46553973 | ||
| Intranasal insulin improves cognition and modulates beta-amyloid in early AD. | Q46945303 | ||
| Accelerated weight loss may precede diagnosis in Alzheimer disease | Q47322019 | ||
| Stroke and the risk of Alzheimer disease | Q48115889 | ||
| DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption. | Q48253140 | ||
| Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease | Q48270990 | ||
| Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients | Q48485994 | ||
| Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: new cues into the human disease? | Q48704367 | ||
| Developmental and vascular risk factors for Alzheimer's disease | Q49160928 | ||
| Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. | Q50708234 | ||
| The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. | Q51011184 | ||
| Hyperinsulinemia and risk of Alzheimer disease. | Q51526824 | ||
| Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. | Q51803993 | ||
| Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. | Q51936631 | ||
| Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. | Q51985996 | ||
| Plasma C peptide level and cognitive function among older women without diabetes mellitus. | Q51990094 | ||
| Risk factors for Alzheimer's disease: a population-based, longitudinal study in Manitoba, Canada. | Q52019123 | ||
| Diabetes mellitus and the risk of dementia: The Rotterdam Study. | Q53231897 | ||
| Association of metabolic syndrome with Alzheimer disease: a population-based study. | Q53280954 | ||
| Alzheimer disease: Insulin resistance and AD--extending the translational path. | Q53329640 | ||
| Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer's disease: a population-based study of the oldest old. | Q53355969 | ||
| Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type | Q69966121 | ||
| Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study | Q73076616 | ||
| Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging | Q74530815 | ||
| Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein | Q74736370 | ||
| Alzheimer's disease | Q80270542 | ||
| Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration | Q80356946 | ||
| Amyloid beta oligomers induce impairment of neuronal insulin receptors | Q80846857 | ||
| Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies | Q83528586 | ||
| Dementia (including Alzheimer's disease) can be prevented: statement supported by international experts | Q86931358 | ||
| A century of Alzheimer's disease | Q36643414 | ||
| Plasma C-peptide levels and rates of cognitive decline in older, community-dwelling women without diabetes | Q36676336 | ||
| Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes. | Q36742834 | ||
| The epidemiology of adiposity and dementia | Q36789879 | ||
| Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment | Q36789901 | ||
| The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial | Q36825706 | ||
| Metabolic syndrome and cognitive decline in early Alzheimer's disease and healthy older adults | Q36880464 | ||
| Association of adiposity status and changes in early to mid-adulthood with incidence of Alzheimer's disease | Q36970053 | ||
| Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study | Q37022797 | ||
| Adiposity, type 2 diabetes, and Alzheimer's disease | Q37250859 | ||
| Incretin-based therapies for type 2 diabetes mellitus | Q37483473 | ||
| Apolipoprotein E and central nervous system disorders: reviews of clinical findings | Q37812145 | ||
| Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review | Q37813161 | ||
| Cognitive function, dementia and type 2 diabetes mellitus in the elderly | Q37832122 | ||
| Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. | Q37846798 | ||
| Metabolic syndrome, cognitive performance, and dementia. | Q37942431 | ||
| Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease | Q37949572 | ||
| Behind the rosiglitazone controversy | Q37960108 | ||
| The global prevalence of dementia: a systematic review and metaanalysis | Q38073027 | ||
| Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function | Q38422040 | ||
| Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study | Q38433563 | ||
| Insulin-activated Akt rescues Aβ oxidative stress-induced cell death by orchestrating molecular trafficking. | Q39533821 | ||
| Preventing Alzheimer's disease | Q39549596 | ||
| Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. | Q39648063 | ||
| Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders | Q39988561 | ||
| Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study | Q40316491 | ||
| Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies | Q41364742 | ||
| Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. | Q41841220 | ||
| Diabetes, cognitive impairment, and dementia | Q42919491 | ||
| Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study | Q42925712 | ||
| Metabolic syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Ageing | Q43228795 | ||
| Presence of the APOE epsilon4 allele modifies the relationship between type 2 diabetes and cognitive performance: the Maine-Syracuse Study | Q43289323 | ||
| 2014 Alzheimer's disease facts and figures | Q43520458 | ||
| Glucose tolerance status and risk of dementia in the community: the Hisayama study | Q43584777 | ||
| Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study | Q43935519 | ||
| Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects | Q44495085 | ||
| DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats | Q44511158 | ||
| C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones | Q44990813 | ||
| Fasting insulin and incident dementia in an elderly population of Japanese-American men. | Q44995788 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| Alzheimer's disease | Q11081 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 549-60 | |
| P577 | publication date | 2015-01-01 | |
| 2015-03-10 | |||
| P1433 | published in | Clinical Interventions in Aging | Q5133768 |
| P1476 | title | Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment | |
| P478 | volume | 10 |
| Q90105404 | A 2-year Double-Blind RCT Follow-up Study with Fermented Papaya Preparation (FPP) Modulating Key Markers in Middle-Age Subjects with Clustered Neurodegenerative Disease-Risk Factors |
| Q57787227 | A new era for understanding amyloid structures and disease |
| Q55353865 | Alzheimer's Disease and Type 2 Diabetes: A Critical Assessment of the Shared Pathological Traits. |
| Q64060113 | Alzheimer's disease: risk factors and potentially protective measures |
| Q46455298 | Ameliorating effect of anti-Alzheimer's drugs on the bidirectional association between type 2 diabetes mellitus and Alzheimer's disease. |
| Q33624944 | Antioxidant and Anti-Senescence Effect of Metformin on Mouse Olfactory Ensheathing Cells (mOECs) May Be Associated with Increased Brain-Derived Neurotrophic Factor Levels-An Ex Vivo Study. |
| Q91836850 | Cognitive dysfunction: A growing link between diabetes and Alzheimer's disease |
| Q36877327 | Current concepts regarding developmental mechanisms in diabetic retinopathy in Taiwan |
| Q90702204 | DPP-4 inhibitors: a promising therapeutic approach against Alzheimer's disease |
| Q96136899 | Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone |
| Q39260245 | Diabetes, adult neurogenesis and brain remodeling: New insights from rodent and zebrafish models |
| Q60913197 | Different risk factors for cognitive impairment among community-dwelling elderly, with impaired fasting glucose or diabetes |
| Q92320078 | Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus |
| Q64230377 | Effects and Underlying Mechanisms of Bioactive Compounds on Type 2 Diabetes Mellitus and Alzheimer's Disease |
| Q57476111 | Effects of Meditation and Music-Listening on Blood Biomarkers of Cellular Aging and Alzheimer's Disease in Adults with Subjective Cognitive Decline: An Exploratory Randomized Clinical Trial |
| Q90049627 | Engineering probiotics as living diagnostics and therapeutics for improving human health |
| Q92559598 | Impacts of nurse-led clinic and nurse-led prescription on hemoglobin A1c control in type 2 diabetes: A meta-analysis |
| Q43182104 | Importance of hypoglycemia on the risk of Alzheimer's disease in elderly subjects with diabetes mellitus |
| Q50020967 | In Silico Preliminary Association of Ammonia Metabolism Genes GLS, CPS1, and GLUL with Risk of Alzheimer's Disease, Major Depressive Disorder, and Type 2 Diabetes |
| Q94450853 | In vitro enzyme inhibitory and cytotoxic studies with Evolvulus alsinoides (Linn.) Linn. Leaf extract: a plant from Ayurveda recognized as Dasapushpam for the management of Alzheimer's disease and diabetes mellitus |
| Q38790379 | Inflammatory Response in the CNS: Friend or Foe? |
| Q39042377 | Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer's Disease |
| Q37343162 | Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults |
| Q38980167 | Insulin signalling in Alzheimer's disease and diabetes: from epidemiology to molecular links. |
| Q38869928 | Insulin-degrading enzyme: new therapeutic target for diabetes and Alzheimer's disease? |
| Q46320626 | Intermittent hypoxia training: Powerful, non-invasive cerebroprotection against ethanol withdrawal excitotoxicity |
| Q64264350 | Is the Brain a Key Player in Glucose Regulation and Development of Type 2 Diabetes? |
| Q64270178 | Korean Thistle ( var. (Maxim.) Matsum.): A Potential Dietary Supplement against Diabetes and Alzheimer's Disease |
| Q38663285 | Low-Molecular-Weight NGF Mimetic Corrects the Cognitive Deficit and Depression-like Behavior in Experimental Diabetes |
| Q37569276 | Metabolic relationship between diabetes and Alzheimer's Disease affected by Cyclo(His-Pro) plus zinc treatment |
| Q41971562 | Metformin Alleviated Aβ-Induced Apoptosis via the Suppression of JNK MAPK Signaling Pathway in Cultured Hippocampal Neurons |
| Q61801352 | Metformin and the Risk of Dementia in Type 2 Diabetes Patients |
| Q36244982 | Models and mechanisms of vascular dementia |
| Q91781508 | Modifiable Risk Factors for Alzheimer's Disease |
| Q38733628 | Molecular Interaction of Anti-Diabetic Drugs With Acetylcholinesterase and Sodium Glucose Co-Transporter 2. |
| Q102053979 | Molecular pathophysiology of diabetes mellitus during pregnancy with antenatal complications |
| Q92715892 | Neurometabolic Evidence Supporting the Hypothesis of Increased Incidence of Type 3 Diabetes Mellitus in the 21st Century |
| Q92925351 | Neuroprotective Effects of the Amylin Analog, Pramlintide, on Alzheimer's Disease Are Associated with Oxidative Stress Regulation Mechanisms |
| Q47221225 | Nuclear Factor-Kappa B and Alzheimer Disease, Unifying Genetic and Environmental Risk Factors from Cell to Humans |
| Q41986529 | Obesity as a risk factor for Alzheimer's disease: weighing the evidence |
| Q92128876 | PPARs as Nuclear Receptors for Nutrient and Energy Metabolism |
| Q64894144 | Pathophysiological abnormalities in the brains of Spontaneously Diabetic Torii-Lepr fa (SDT fatty) rats, a novel type 2 diabetic model. |
| Q90835950 | Pentacyclic triterpenoid-rich fraction of the Hardy kiwi (Actinidia arguta) improves brain dysfunction in high fat diet-induced obese mice |
| Q37204006 | Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease. |
| Q59127002 | Pioglitazone Reduces Dementia Risk in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Analysis |
| Q51805155 | Polymorphic cross-seeding amyloid assemblies of amyloid-β and human islet amyloid polypeptide. |
| Q64781347 | Pre-structured hydrophobic peptide β-strands: A universal amyloid trap? |
| Q55396744 | Probiotics improve insulin resistance status in an experimental model of Alzheimer's disease. |
| Q39931530 | Protective Effects of Colivelin Against Alzheimer's Disease in a PDAPP Mouse Model |
| Q38734185 | Receptor-mediated toxicity of human amylin fragment aggregated by short- and long-term incubations with copper ions |
| Q37325631 | Relationship between oxysterols and mild cognitive impairment in the elderly: a case-control study |
| Q91997167 | Rosiglitazone has a neutral effect on the risk of dementia in type 2 diabetes patients |
| Q90091568 | Shared Causal Paths underlying Alzheimer's dementia and Type 2 Diabetes |
| Q37502130 | The Role of Cardiovascular Risk Factors and Stroke in Familial Alzheimer Disease |
| Q89843230 | Type 2 Diabetes and Chronic Conditions Disparities in Medicare Beneficiaries in the State of Michigan |
Search more.